How Ketamine Therapy Works for Treatment-Resistant Depression

A patient has tried six different antidepressants over four years. Each one either stopped working or triggered intolerable side effects. After a psychiatrist mentions ketamine, they ask a simple question: why would an anesthetic used in emergency rooms help depression that conventional drugs could not?

The framework for thinking about ketamine as depression treatment

Ketamine differs from traditional antidepressants in three critical dimensions: mechanism of action, speed of effect, and FDA approval pathway. Most conventional antidepressants work by increasing serotonin or norepinephrine availability over weeks or months. Ketamine operates through a separate neurochemical pathway, producing measurable mood improvement within hours. Understanding these distinctions separates evidence-based clinical use from misconception.

How ketamine blocks depression at the neurological level

“The N-methyl-D-aspartate (NMDA) receptor has a major role in the neurophysiology of depression.” Ketamine antagonizes this receptor, reducing glutamate-driven excitotoxicity in the prefrontal cortex and hippocampus. This action differs fundamentally from serotonin reuptake inhibition. By dampening overactive glutamate signaling, ketamine restores synaptic plasticity and allows the brain to form new neural connections associated with mood improvement. The mechanism enables rapid antidepressant effects without the delayed cascade required by monoamine-based drugs.

Following NMDA blockade, ketamine triggers downstream activation of the mammalian target of rapamycin (mTOR) pathway, which strengthens synaptic connections and promotes brain-derived neurotrophic factor (BDNF) release. This neuroprotective cascade appears to underlie sustained mood recovery. Patients report improvement even after the ketamine metabolizes from their system, suggesting structural changes rather than acute chemical masking.

Speed and durability of treatment response

“Placebo-controlled trials have provided strong evidence for the rapid-acting (within hours) and sustained (lasting up to 7 days) antidepressant effect…”  This timeline separates ketamine from all first-line antidepressants, which typically require 4 to 8 weeks before symptom relief. For acutely suicidal patients, hours matter. Ketamine’s rapid onset makes it a bridge therapy during psychiatric crises. The 7-day window allows clinicians to stabilize patients and establish conventional medication regimens or psychotherapy that may provide longer-term benefit.

Esketamine, the FDA-approved nasal spray formulation, demonstrates sustained efficacy across multiple administrations. Clinical protocols involve two to three infusions or nasal doses per week for the first month, then tapering based on individual response. Some patients require maintenance dosing every 2 to 4 weeks indefinitely; others achieve durable remission after an induction phase.

FDA approval status and clinical eligibility

“For the first time in 60 years, we have a new antidepressant therapy that isn’t just a spinoff of existing drugs,” says Adam Kaplin, M.D., Ph.D., a psychiatrist at Johns Hopkins Medicine. The FDA approved esketamine (Spravato) in March 2019 for treatment-resistant depression, defined as failure to respond to at least two different antidepressants at adequate doses and duration. As of Q1 2026, esketamine remains the only ketamine-derived product with FDA approval for psychiatric use, though intravenous ketamine and intranasal racemic ketamine operate in clinical settings under off-label protocols.

Treatment-resistant depression affects approximately 30% of patients with major depressive disorder. The approval pathway for esketamine included requirements for in-clinic administration with medical observation for 2 hours post-dose, reflecting ketamine’s dissociative properties and abuse potential. This safeguard distinguishes approved ketamine from the street formulation.

Conditions beyond major depression showing response

Esketamine and off-label ketamine demonstrate efficacy in bipolar depression, a condition notoriously resistant to standard antidepressants, which may destabilize mood cycling or trigger manic episodes. Emerging evidence suggests benefit in post-traumatic stress disorder and suicidal ideation, though these indications remain under active research. Major depressive disorder with acute suicidality represents the strongest evidence base outside treatment-resistant depression proper.

Safety profile and patient concerns

Ketamine carries documented risks requiring careful patient selection and monitoring. Dissociation during infusion (feeling detached from one’s body or surroundings) is common and typically resolves within 2 hours. Nasal esketamine reduces but does not eliminate this effect. Longer-term concerns include potential cognitive effects and abuse liability, though clinical populations under supervision show low addiction rates. Contraindications include uncontrolled hypertension, active substance use disorder, and certain cardiac arrhythmias.

Clinics offering ketamine therapy, including providers like lidowellnesscenter.com, now screen patients for medical and psychiatric safety before enrollment. Informed consent discussions cover dissociation, blood pressure monitoring, and realistic timelines for improvement.

Synthesis: what this means for treatment-seeking patients and clinicians

For patients exhausted by failed medication trials, ketamine represents a pharmacologically distinct option with rapid onset and evidence of efficacy. The narrow FDA approval window (treatment-resistant major depression) reflects genuine clinical need rather than off-label scope creep. Clinicians should consider ketamine only after documenting adequate trials of two first-line agents and ruling out medical contraindications.

The 80/20 breakdown

Eighty percent of ketamine’s clinical benefit derives from NMDA antagonism and subsequent mTOR pathway activation, both achieved within the first infusion or nasal dose. The remaining 20% comes from repeated dosing to consolidate synaptic changes and extend remission. Clinicians should prioritize rigorous patient selection and baseline safety screening; induction frequency and tapering schedules matter less than identifying appropriate candidates.

Frequently asked questions

How is ketamine-assisted psychotherapy different from ketamine treatment alone? Ketamine-assisted psychotherapy pairs medication administration with concurrent or follow-up talk therapy, theoretically capitalizing on enhanced neuroplasticity to embed behavioral change. Evidence for this combined model remains preliminary. Most FDA-approved esketamine protocols include psychotherapy recommendation but not mandate.

Can I use ketamine at home? No. Esketamine nasal spray must be administered in a certified clinical setting with 2-hour medical observation. IV ketamine requires infusion center access. Off-label oral or intranasal ketamine at home falls outside supervised clinical protocols and carries unmonitored dissociation and cardiovascular risks.

What happens if ketamine stops working? Tachyphylaxis (diminishing response with repeated doses) occurs in some patients after weeks or months. Clinicians may adjust dosing, extend intervals, or combine ketamine with other medications. A small percentage of patients show no initial response and require alternative strategies.

Is ketamine addictive? Patients under clinical supervision show low addiction rates despite ketamine’s abuse potential. The dissociative effects and structured dosing in supervised settings reduce reinforcement compared to street use. Patients with active substance use disorder generally should not receive ketamine therapy.

How long does remission last after ketamine treatment stops? Duration varies widely. Some patients maintain improvement for months after induction; others require maintenance doses every 2 to 4 weeks indefinitely. Concurrent antidepressant or psychotherapy support appears to extend remission windows.

Are there any long-term cognitive side effects? Long-term safety data in psychiatric populations remains limited. No consensus exists on permanent cognitive damage from therapeutic ketamine use, though acute dissociation and short-term memory effects during treatment are documented.

When should I consider ketamine instead of trying another antidepressant? Only after documented failure of two adequate antidepressant trials. Ketamine’s cost, monitoring requirements, and dissociative effects make it a second-line or third-line option. Clinicians should rule out medical contraindications and active substance use before referral.

Does insurance cover esketamine? Coverage varies by plan and insurer. Many require prior authorization and documentation of two failed antidepressant trials. Out-of-pocket costs typically range $4,000 to $10,000 for a full induction course.

Ready to Talk About Your Options?

If depression hasn’t improved with treatment, you deserve a careful look at what comes next. The team at Lido Wellness Center in Newport Beach can help you discuss your symptoms, treatment history, and options for care. Contact us online or call  949-541-8466 to start the conversation.